Immix Biopharma (NASDAQ:IMMX - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright's price objective indicates a potential upside of 195.36% from the stock's previous close. HC Wainwright also issued estimates for Immix Biopharma's Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.62) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.65) EPS.
Immix Biopharma Price Performance
IMMX stock traded up $0.18 during mid-day trading on Wednesday, reaching $2.37. 185,785 shares of the company's stock were exchanged, compared to its average volume of 155,177. The company has a market cap of $66.07 million, a price-to-earnings ratio of -2.79 and a beta of 0.31. The stock's 50 day moving average is $1.91 and its 200 day moving average is $1.95. Immix Biopharma has a 12-month low of $1.26 and a 12-month high of $3.00.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09. On average, research analysts forecast that Immix Biopharma will post -0.87 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Immix Biopharma
A hedge fund recently bought a new stake in Immix Biopharma stock. Jane Street Group LLC bought a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 17,523 shares of the company's stock, valued at approximately $39,000. Jane Street Group LLC owned about 0.06% of Immix Biopharma as of its most recent SEC filing. 11.26% of the stock is owned by hedge funds and other institutional investors.
Immix Biopharma Company Profile
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Read More
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
